1. Home
  2. LNN vs PHAT Comparison

LNN vs PHAT Comparison

Compare LNN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lindsay Corporation

LNN

Lindsay Corporation

HOLD

Current Price

$116.11

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$8.70

Market Cap

969.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNN
PHAT
Founded
1954
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
969.8M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
LNN
PHAT
Price
$116.11
$8.70
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$113.00
$19.83
AVG Volume (30 Days)
93.4K
1.8M
Earning Date
04-02-2026
04-30-2026
Dividend Yield
1.35%
N/A
EPS Growth
12.81
42.72
EPS
4.22
N/A
Revenue
$676,368,000.00
$175,110,000.00
Revenue This Year
N/A
$93.04
Revenue Next Year
$4.74
$58.91
P/E Ratio
$27.53
N/A
Revenue Growth
11.41
216.93
52 Week Low
$97.27
$8.21
52 Week High
$148.00
$18.31

Technical Indicators

Market Signals
Indicator
LNN
PHAT
Relative Strength Index (RSI) 53.27 40.24
Support Level $115.48 $8.21
Resistance Level $120.01 $12.07
Average True Range (ATR) 3.09 0.47
MACD 0.22 0.04
Stochastic Oscillator 54.57 35.83

Price Performance

Historical Comparison
LNN
PHAT

About LNN Lindsay Corporation

Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: